Former Gates Foundation and Baxter Executive Peter H. Khoury, Ph.D. Joins Nanotherapeutics as Chief Commercial Officer

2017-11-29T23:05:50-05:00August 3rd, 2016|

Former Gates Foundation and Baxter Executive Peter H. Khoury, Ph.D. Joins Nanotherapeutics as Chief Commercial Officer ALACHUA, Fla.--(BUSINESS WIRE)--Nanotherapeutics, Inc., a contract development and manufacturing organization (CDMO), announced today that Peter Khoury, Ph.D. has joined the Company as Senior Vice President and Chief Commercial Officer, effective August 1, 2016. “We are delighted [...]

Nanotherapeutics Closes Sale-Leaseback Financing with Senior Housing Properties Trust for the Company’s New Advanced Development and Manufacturing Facility in Alachua, FL

2017-11-29T23:33:20-05:00May 6th, 2016|

Nanotherapeutics Closes Sale-Leaseback Financing with Senior Housing Properties Trust for the Company’s New Advanced Development and Manufacturing Facility in Alachua, FL ALACHUA, Fla.--(BUSINESS WIRE)--Nanotherapeutics, an integrated biopharmaceutical company with a focus on advanced development and manufacturing, today announced the closing of a sale-leaseback transaction with Senior Housing Properties Trust, or SNH, for [...]

Nanotherapeutics CEO is Guest Panelist at FBR’s Health Series Conference

2017-11-29T23:34:18-05:00April 26th, 2016|

Nanotherapeutics CEO is Guest Panelist at FBR’s Health Series Conference ALACHUA, FL April 22, 2016. On April 20, FBR hosted a thematic conference featuring 16 guest speakers in four panels to discuss key topics related to infections and diseases, and provided investors a rare opportunity to interact with Robin Robinson, Ph.D., who [...]

Governor Scott Highlights Recent Job Growth at Nanotherapeutics, Inc.

2017-11-29T23:36:24-05:00April 6th, 2016|

Governor Scott Highlights Recent Job Growth at Nanotherapeutics, Inc. ALACHUA, Fla. – Today, Governor Rick Scott highlighted recent job growth at Nanotherapeutics, Inc., a biopharmaceutical company. In 2013, Governor Scott announced that Nanotherapeutics would be expanding to create 150 new jobs at their new manufacturing facility with a capital investment of $122 [...]

Nanotherapeutics to host interactive mini-symposium about Monoclonal Antibody Technology

2017-11-29T23:37:48-05:00March 10th, 2016|

On March 21st, 2016, Nanotherapeutics will host an interactive mini-symposium devoted to the use of Monoclonal Antibody Technology for Development of Medical Countermeasures.  Specific emphasis will be on the development of monoclonal antibodies against Botulinum Neurotoxins, as part of the Advanced Development and Manufacturing of Antibody Technologies (ADAMANT) concept.  This meeting will take place at the Nanotherapeutics-Maryland office located at 8490 Progress Drive, Suite 150, Frederick, MD 21701.  The meeting will begin at 10:00 a.m. and will conclude at 1:00 p.m.

Zika Virus: Medical Countermeasure Development Challenges has published in PLOS!

2017-11-29T23:40:38-05:00March 4th, 2016|

Zika Virus: Medical Countermeasure Development Challenges has published in PLOS! Reports of high rates of primary microcephaly and Guillain–Barré syndrome associated with Zika virus infection in French Polynesia and Brazil have raised concerns that the virus circulating in these regions is a rapidly developing neuropathic, teratogenic, emerging infectious public health threat. There [...]

Nanotherapeutics Grants Worldwide Rights to Amend Surgical, Inc. for NanoFUSE® DBM

2017-11-29T23:42:05-05:00January 6th, 2016|

Nanotherapeutics Grants Worldwide Rights to Amend Surgical, Inc. for NanoFUSE® DBM ALACHUA, Fla.--(BUSINESS WIRE)--Nanotherapeutics, Inc., an integrated biopharmaceutical company with a focus on advanced development and manufacturing, today announced that the Company has granted an exclusive worldwide license to its proprietary bone void filler product, NanoFUSE® DBM (demineralized bone matrix), to Alachua, FL-based Amend [...]

XOMA’s divests biodefense program to Nanotherapeutics, Inc.

2019-04-15T18:00:06-04:00November 5th, 2015|

BERKELEY, Calif., Nov. 5, 2015 -- XOMA Corporation (XOMA), a leader in the discovery and development of therapeutic antibodies, announced today it has agreed to sell its biologics manufacturing facilities, equipment, and associated real estate to Agenus Inc. (AGEN). The transaction is expected to close in December 2015. In conjunction with the transaction, Agenus will [...]

Takeda and Nanotherapeutics Announce Agreement to Expand Takeda’s Commercialization and Technology Access Rights in Support of Influenza and Other Vaccine Programs

2015-08-26T20:08:52-04:00August 26th, 2015|

ALACHUA, Fla. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (Takeda) (TOKYO: 4502) and Nanotherapeutics, Inc., announced an agreement providing Takeda with expanded commercialization and technology access rights related to Nanotherapeutics’ Vero cell technology platform – a cell culture-based platform for vaccine production which Nanotherapeutics acquired from Baxalta, formerly Baxter International’s BioScience division. Financial terms of [...]

Nanotherapeutics Awarded BARDA Fill-Finish Manufacturing Network Task Orders to Develop Two FDA Drug Shortage Products

2015-07-10T09:36:44-04:00July 10th, 2015|

ALACHUA, Fla.--(BUSINESS WIRE)--Nanotherapeutics, Inc., a global manufacturer of biodefense and infectious disease products, announced today that it has received two new Task Orders from The United States Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA) Fill-Finish Manufacturing Network’s (FFMN) Pilot Production program, for the Center for Drug Evaluation and [...]

Go to Top